Literature DB >> 21899208

Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model.

Jorge E Toblli1, Gabriel Cao, Leda Oliveri, Margarita Angerosa.   

Abstract

Intravenous (i.v.) iron is associated with a risk of oxidative stress. The effects of ferumoxytol, a recently approved i.v. iron preparation, were compared with those of ferric carboxymaltose, low molecular weight iron dextran and iron sucrose in the liver, kidneys and heart of normal rats. In contrast to iron sucrose and ferric carboxymaltose, low molecular weight iron dextran and ferumoxytol caused renal and hepatic damage as demonstrated by proteinuria and increased liver enzyme levels. Higher levels of oxidative stress in these tissues were also indicated, by significantly higher levels of malondialdehyde, significantly increased antioxidant enzyme activities, and a significant reduction in the reduced to oxidized glutathione ratio. Inflammatory markers were also significantly higher with ferumoxytol and low molecular weight iron dextran rats than iron sucrose and ferric carboxymaltose. Polarographic analysis suggested that ferumoxytol contains a component with a more positive reduction potential, which may facilitate iron-catalyzed formation of reactive oxygen species and thus be responsible for the observed effects. Only low molecular weight iron dextran induced oxidative stress and inflammation in the heart.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21899208     DOI: 10.1055/s-0031-1296218

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  10 in total

Review 1.  Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations.

Authors:  Ankit Shah; Marina A Dobrovolskaia
Journal:  Nanomedicine       Date:  2018-02-02       Impact factor: 5.307

Review 2.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

Review 3.  Safety of intravenous iron in hemodialysis patients.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Hemodial Int       Date:  2017-04-03       Impact factor: 1.812

4.  The Induction of Oxidative/Nitrosative Stress, Inflammation, and Apoptosis by a Ferric Carboxymaltose Copy Compared to Iron Sucrose in a Non-Clinical Model.

Authors:  Jorge E Toblli; Gabriel Cao; Margarita Angerosa
Journal:  J Clin Diagn Res       Date:  2015-12-01

5.  In vitro and in vivo DFO-chelatable labile iron release profiles among commercially available intravenous iron nanoparticle formulations.

Authors:  Amy Barton Pai; Manjunath P Pai; Dan E Meyer; Brian C Bales; Victoria E Cotero; Nan Zheng; Wenlei Jiang
Journal:  Regul Toxicol Pharmacol       Date:  2018-05-29       Impact factor: 3.271

6.  Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud?

Authors:  Amy Barton Pai; Adinoyi O Garba
Journal:  J Blood Med       Date:  2012-08-29

Review 7.  Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.

Authors:  Jorge Eduardo Toblli; Margarita Angerosa
Journal:  Drug Des Devel Ther       Date:  2014-12-11       Impact factor: 4.162

Review 8.  Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?

Authors:  Theresa McDonagh; Iain C Macdougall
Journal:  Eur J Heart Fail       Date:  2015-01-30       Impact factor: 15.534

9.  Cardiovascular, liver, and renal toxicity associated with an intravenous ferric carboxymaltose similar versus the originator compound.

Authors:  Jorge E Toblli; Gabriel Cao; Luis Rico; Margarita Angerosa
Journal:  Drug Des Devel Ther       Date:  2017-11-30       Impact factor: 4.162

10.  Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.

Authors:  Jorge E Toblli; Gabriel Cao; Jorge F Giani; Fernando P Dominici; Margarita Angerosa
Journal:  Drug Des Devel Ther       Date:  2017-08-01       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.